Category Archives: Recent News

BriaCell to utilize ImaginAb’s CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells

BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer NEW ...

BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

NEW YORK and VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell to Present at Three Upcoming Investor Conferences

BERKELEY, Calif. and VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th – 15th, 2021

RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving – an investor conference ...

BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma, and ...

BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises

Proceeds will be used to advance clinical and research and development pipeline and for general ...

BriaCell to Host Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET

BERKELEY, Calif. and VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement

BERKELEY, Calif. and VANCOUVER, British Columbia, June 07, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. ...

BriaCell Therapeutics Corp. Announces US$27.2 Million Private Placement

BERKELEY, Calif. and VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. ...

BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor

12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches ...